赛伦生物融资活跃资金流入，前三季度业绩微增

Core Viewpoint - Sirun Biotech has been actively engaged in financing activities, with a stable fundamental performance, while the pharmaceutical and biotechnology sector is receiving overall policy support [1]. Group 1: Funding Trends - Financing activities have been active, with Sirun Biotech receiving a financing buy-in of 1.6125 million yuan on January 22, 2026, bringing the financing balance to 151 million yuan, which accounts for 5.54% of the circulating market value [2]. - On January 9, 2026, there was a net inflow of 979,400 yuan in main funds, indicating a shift from outflow to inflow compared to the previous trading day, coinciding with a 1.58% increase in the pharmaceutical and biotechnology sector [2]. - Earlier, on January 6, 2026, a net inflow of 1.1276 million yuan was also observed [2]. Group 2: Performance and Operations - For the first three quarters of 2025, the company achieved an operating income of 175 million yuan, representing a year-on-year growth of 1.07%, and a net profit attributable to shareholders of 64.2107 million yuan, up 2.01% year-on-year [3]. - As of September 30, 2025, the number of shareholders was 6,635, a decrease of 14.10% compared to the previous period [3]. - The first quarter report of 2025 indicated a net profit attributable to shareholders of 3.7573 million yuan, a significant year-on-year increase of 154.77%, although total operating revenue saw a decline of 2.59% year-on-year [3]. Group 3: Company Status - As of October 31, 2025, Sirun Biotech's ESG rating was CCC, ranking 63rd in the biotechnology industry, with a low score in the environmental category [4]. Group 4: Industry Policy Environment - The pharmaceutical and biotechnology sector is benefiting from policy support and the trend of an aging population, with strong sector performance observed in early January 2026, which may indirectly influence individual stock fund flows [5]. - The company's main business focuses on the field of antiserum and antitoxin, characterized by a single product line but with high barriers to entry in the niche market [5].